{"lastUpdatedAt": 1611091606003, "totalPosts": {"label": "Total Posts", "value": 104}, "totalComments": {"label": "Total Comments", "value": 1763}, "postRate": {"title": "Post Rate", "data": [{"label": "2021-01-18T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T02:00:00.000+05:30", "value": 6}, {"label": "2021-01-18T03:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T04:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T07:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T09:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T11:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T13:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T14:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T17:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T18:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T19:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T20:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T21:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T22:00:00.000+05:30", "value": 4}, {"label": "2021-01-18T23:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T00:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-19T02:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T03:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T04:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T07:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T09:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T12:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T13:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T15:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T17:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T18:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T19:00:00.000+05:30", "value": 5}, {"label": "2021-01-19T20:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T21:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T22:00:00.000+05:30", "value": 5}, {"label": "2021-01-19T23:00:00.000+05:30", "value": 3}, {"label": "2021-01-20T00:00:00.000+05:30", "value": 4}]}, "commentRate": {"title": "Comment Rate", "data": [{"label": "2021-01-19T23:00:00.000+05:30", "value": 216}, {"label": "2021-01-20T00:00:00.000+05:30", "value": 527}, {"label": "2021-01-20T01:00:00.000+05:30", "value": 633}, {"label": "2021-01-20T02:00:00.000+05:30", "value": 387}]}, "commentSentiments": {"title": "Comment Sentiments", "data": [{"name": "neutral", "value": 810}, {"name": "positive", "value": 680}, {"name": "negative", "value": 273}]}, "postSentiments": {"title": "Post Sentiments", "data": [{"name": "neutral", "value": 64}, {"name": "positive", "value": 33}, {"name": "negative", "value": 7}]}, "topStocks": {"title": "Top stocks", "data": [{"label": "TRCH", "value": 4}, {"label": "SNDL", "value": 4}, {"label": "CIDM", "value": 4}, {"label": "BNGO", "value": 4}, {"label": "ATOS", "value": 4}, {"label": "LPCN", "value": 5}, {"label": "PT", "value": 8}, {"label": "MOTS", "value": 9}, {"label": "ZYXI", "value": 93}]}, "stockRatings": {"title": "Stock Ratings", "data": {"TRCH": {"score": {"P/B": 5, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Strong Buy", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "SNDL": {}, "CIDM": {"score": {"P/B": 3, "ROA": 5, "DCF": 5, "P/E": 3, "ROE": 5, "D/E": 5}, "recommendation": {"P/B": "Neutral", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Strong Buy", "D/E": "Strong Buy"}}, "BNGO": {}, "ATOS": {"score": {"P/B": 3, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Neutral", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "LPCN": {"score": {"P/B": 5, "ROA": 2, "DCF": 4, "P/E": 3, "ROE": 2, "D/E": 4}, "recommendation": {"P/B": "Strong Buy", "ROA": "Buy", "DCF": "Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "PT": {}, "MOTS": {"score": {"P/B": 5, "ROA": 2, "DCF": 4, "P/E": 3, "ROE": 2, "D/E": 4}, "recommendation": {"P/B": "Strong Buy", "ROA": "Buy", "DCF": "Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "ZYXI": {}}}, "enterprise": {"title": "Enterprise History", "data": {"TRCH": {"symbol": "TRCH", "stockPrice": 0.62, "numberOfShares": 72857079, "marketCapitalization": 45171388.98, "minusCashAndCashEquivalents": 89730, "addTotalDebt": 11871934, "enterpriseValue": 56953592.98}, "SNDL": {"addTotalDebt": 16227000, "enterpriseValue": 100372500, "marketCapitalization": 129482500, "minusCashAndCashEquivalents": 45337000, "numberOfShares": 85750000, "stockPrice": 1.51, "symbol": "SNDL"}, "CIDM": {"symbol": "CIDM", "stockPrice": 1.92, "numberOfShares": 37919754, "marketCapitalization": 72805927.67999999, "minusCashAndCashEquivalents": 17872000, "addTotalDebt": 19132000, "enterpriseValue": 74065927.67999999}, "BNGO": {"symbol": "BNGO", "stockPrice": 1.09, "numberOfShares": 34274469, "marketCapitalization": 37359171.21, "minusCashAndCashEquivalents": 17311373, "addTotalDebt": 0, "enterpriseValue": 20047798.21}, "ATOS": {"symbol": "ATOS", "stockPrice": 1.44, "numberOfShares": 8496964, "marketCapitalization": 12235628.16, "minusCashAndCashEquivalents": 12581136, "addTotalDebt": 0, "enterpriseValue": -345507.83999999985}, "LPCN": {"symbol": "LPCN", "stockPrice": 0.454, "numberOfShares": 25882273, "marketCapitalization": 11750551.942, "minusCashAndCashEquivalents": 9728523, "addTotalDebt": 8154448, "enterpriseValue": 10176476.942}, "PT": {"symbol": "PT", "stockPrice": 2.51, "numberOfShares": 40304238, "marketCapitalization": 101163637.38, "minusCashAndCashEquivalents": 102755000, "addTotalDebt": 192872000, "enterpriseValue": 191280637.38}, "MOTS": {"symbol": "MOTS", "stockPrice": 2.02, "numberOfShares": 25133190, "marketCapitalization": 50769043.8, "minusCashAndCashEquivalents": 20528000, "addTotalDebt": 8203000, "enterpriseValue": 38444043.8}, "ZYXI": {"symbol": "ZYXI", "stockPrice": 9.73, "numberOfShares": 32439000, "marketCapitalization": 315631470, "minusCashAndCashEquivalents": 14040000, "addTotalDebt": 0, "enterpriseValue": 301591470}}}, "profile": {"title": "Company Profile", "data": {"TRCH": {"symbol": "TRCH", "price": 1.51, "beta": 2.41048, "volAvg": 5581227, "mktCap": 150458208, "lastDiv": 0.0, "range": "0.21-1.58", "changes": 0.14, "companyName": "Torchlight Energy Resources Inc", "currency": "USD", "cik": "0001431959", "isin": "US89102U1034", "cusip": "89102U103", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Oil & Gas E&P", "website": "https://www.torchlightenergy.com/", "description": "Torchlight Energy Resources, Inc. engages in the acquisition, exploration, exploitation and development of oil and natural gas properties in the United States. The company is headquartered in Plano, Texas and currently employs 2 full-time employees. The firm focuses on drilling and working interest programs within the United States. The firm has interests in approximately four oil and gas projects: the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; Hunton wells in partnership with Husky Ventures in Central Oklahoma, and the Orogrande Project in Hudspeth County, Texas. The firm also operates through two other subsidiaries, including Torchlight Energy Operating, LLC, a Texas limited liability company, and Hudspeth Oil Corporation, a Texas corporation. The Marcelina Creek Field Development is located over the Austin Chalk, Buda and Eagle Ford Formations.", "ceo": "Mr. John Brda", "sector": "Energy", "country": "US", "fullTimeEmployees": "4", "phone": "12144328002", "address": "5700 W Plano Pkwy Ste 3600", "city": "Plano", "state": "TEXAS", "zip": "75093", "dcfDiff": null, "dcf": 0.0, "image": "https://financialmodelingprep.com/image-stock/TRCH.png", "ipoDate": "2009-10-27", "defaultImage": false}, "SNDL": {"symbol": "SNDL", "price": 0.684299, "beta": 0.0, "volAvg": 308493666, "mktCap": 709823300, "lastDiv": 0.0, "range": "0.138-3.88", "changes": -0.029301, "companyName": "Sundial Growers Inc", "currency": "CAD", "cik": "0001766600", "isin": "CA86730L1094", "cusip": "86730L109", "exchange": "NasdaqGS", "exchangeShortName": "NASDAQ", "industry": "Drug Manufacturers General Specialty & Generic", "website": "https://www.sundialcannabis.com/", "description": "Sundial Growers Inc. engages in the production, distribution, and sale of cannabis products for the adult-use market It is also involved in the production, distribution, and sale of ornamental plants and herbs in the United Kingdom. The company offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.", "ceo": "Mr. Zachary Ryan George IV", "sector": "Healthcare", "country": "CA", "fullTimeEmployees": "868", "phone": "14039485227", "address": "919 11 Ave SW Suite 200", "city": "Calgary", "state": "ALBERTA", "zip": "T2R 1P3", "dcfDiff": null, "dcf": null, "image": "https://financialmodelingprep.com/image-stock/SNDL.jpg", "ipoDate": "2019-08-01", "defaultImage": true}, "CIDM": {"symbol": "CIDM", "price": 1.1, "beta": 1.83276, "volAvg": 12243996, "mktCap": 146368208, "lastDiv": 0.0, "range": "0.25-6.0", "changes": 0.274, "companyName": "Cinedigm Corp", "currency": "USD", "cik": "0001173204", "isin": "US1724062096", "cusip": "172406209", "exchange": "NASDAQ Global Market", "exchangeShortName": "NASDAQ", "industry": "Entertainment", "website": "http://www.cinedigm.com", "description": "Cinedigm Corp. engages in the marketing and distribution of movie, television, and other short form content managing a library of distribution rights. The company is headquartered in New York City, New York and currently employs 104 full-time employees. The firm also provides digital cinema assets servicing on over 12,000 domestic and foreign movie screens. The company operates through four segments: first digital cinema deployment (Phase I Deployment), the second digital cinema deployment (Phase II Deployment), digital cinema services and media content and entertainment group. The company collaborates with producers, brands and other content owners to market, source, curate and distribute content to targeted audiences. The company distributes content through existing and emerging digital home entertainment platforms and packaged distribution of DVD and Blu-ray discs to wholesalers and retailers and mortar storefronts. The company also operates a branded and curated over-the-top entertainment channels.", "ceo": "Mr. Christopher McGurk", "sector": "Communication Services", "country": "US", "fullTimeEmployees": "70", "phone": "12122068600", "address": "237 WEST 35TH STREET, SUITE 605", "city": "New York City", "state": "NEW YORK", "zip": "10018", "dcfDiff": 4.54, "dcf": 6.49, "image": "https://financialmodelingprep.com/image-stock/CIDM.png", "ipoDate": "2006-04-18", "defaultImage": false}, "BNGO": {"symbol": "BNGO", "price": 9.14, "beta": 0.0, "volAvg": 63079645, "mktCap": 2079185540, "lastDiv": 0.0, "range": "0.25-9.95", "changes": 0.71, "companyName": "Bionano Genomics Inc", "currency": "USD", "cik": "0001411690", "isin": "US09075F1075", "cusip": "09075F107", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Diagnostics & Research", "website": "https://bionanogenomics.com/", "description": "BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The company is headquartered in San Diego, California and currently employs 77 full-time employees. The firm develops and markets the Saphyr system. The Company\u2019s products include Sequencing for Discovery Research and Cytogenetics. Sequencing alone, however, is significantly limited due to its inability to reveal structural variations. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response.", "ceo": "DR. R. Erik Holmlin", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "97", "phone": "18588887600", "address": "9540 Towne Centre Dr Ste 100", "city": "San Diego", "state": "CALIFORNIA", "zip": "92121", "dcfDiff": null, "dcf": null, "image": "https://financialmodelingprep.com/image-stock/BNGO.png", "ipoDate": "2018-08-01", "defaultImage": false}, "ATOS": {"symbol": "ATOS", "price": 1.41, "beta": 2.45985, "volAvg": 6160395, "mktCap": 100672304, "lastDiv": 0.0, "range": "0.76-5.08", "changes": 0.16, "companyName": "Atossa Therapeutics Inc", "currency": "USD", "cik": "0001488039", "isin": "US04962H5063", "cusip": "04962H506", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://atossatherapeutics.com/", "description": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.", "ceo": "Dr. Steven Quay", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "4", "phone": "12065880256", "address": "107 Spring St", "city": "Seattle", "state": "WASHINGTON", "zip": "98104", "dcfDiff": -3.47, "dcf": 3.36066, "image": "https://financialmodelingprep.com/image-stock/ATOS.png", "ipoDate": "2012-11-08", "defaultImage": false}, "LPCN": {"symbol": "LPCN", "price": 1.76, "beta": 0.49783, "volAvg": 2462270, "mktCap": 115607712, "lastDiv": 0.0, "range": "0.301-2.39", "changes": 0.14, "companyName": "Lipocine Inc", "currency": "USD", "cik": "0001535955", "isin": "US53630X1046", "cusip": "53630X104", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.lipocine.com/", "description": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.", "ceo": "Dr. Mahesh Patel", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "12", "phone": "18019947383", "address": "675 S Arapeen Dr Ste 202", "city": "Salt Lake City", "state": "UTAH", "zip": "84108", "dcfDiff": null, "dcf": 1.70588, "image": "https://financialmodelingprep.com/image-stock/LPCN.jpg", "ipoDate": "2014-03-21", "defaultImage": true}, "PT": {"symbol": "PT", "price": 1.19, "beta": 0.0, "volAvg": 286280, "mktCap": 51334580, "lastDiv": 0.0, "range": "0.75-3.23", "changes": 0.03, "companyName": "Pintec Technology Holdings Ltd", "currency": "CNY", "cik": "0001716338", "isin": "US72352G1076", "cusip": "72352G107", "exchange": "NasdaqGM", "exchangeShortName": "NASDAQ", "industry": "Credit Services", "website": "https://www.pintec.com", "description": "Pintec Technology Holdings Ltd. engages in the provision of financial services through technology platform. The company is headquartered in Beijing, Beijing and currently employs 362 full-time employees. The firm is located in China.", "ceo": "Mr. Jun Dong", "sector": "Financial Services", "country": "CN", "fullTimeEmployees": "256", "phone": "861085643600", "address": "9/F Heng An Building, No.17 East 3Rd Ring Road", "city": "Beijing", "state": "BEIJING", "zip": null, "dcfDiff": null, "dcf": 10.1899, "image": "https://financialmodelingprep.com/image-stock/PT.png", "ipoDate": "2018-10-25", "defaultImage": false}, "MOTS": {"symbol": "MOTS", "price": 1.75, "beta": 2.069734, "volAvg": 503287, "mktCap": 56422448, "lastDiv": 0.0, "range": "0.46-2.29", "changes": 0.62, "companyName": "Motus GI Holdings Inc", "currency": "USD", "cik": "0001686850", "isin": "US62014P1084", "cusip": "62014P108", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Diagnostics & Research", "website": "https://www.motusgi.com/", "description": "Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. The company is headquartered in Fort Lauderdale, Florida and currently employs 44 full-time employees. The firm is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The Pure-Vu system uses a precise mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high quality examination, even when the patient is not fully clean prior to their procedure. The Pure-Vu System also helps in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon This device fits standard colonoscopes, allowing the physician to clean poorly-prepped colons in a safe and effective manner to gain clear visualization of the colon mucosa.", "ceo": "Mr. Timothy Moran", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "49", "phone": "17864591831", "address": "1301 E Broward Blvd Fl 3", "city": "Fort Lauderdale", "state": "FLORIDA", "zip": "33301", "dcfDiff": null, "dcf": 0.0, "image": "https://financialmodelingprep.com/image-stock/MOTS.png", "ipoDate": "2018-02-14", "defaultImage": false}, "ZYXI": {"symbol": "ZYXI", "price": 18.05, "beta": 0.67852, "volAvg": 533546, "mktCap": 627905340, "lastDiv": 0.0, "range": "7.93-29.73", "changes": 1.53, "companyName": "Zynex Inc", "currency": "USD", "cik": "0000846475", "isin": "US98986M1036", "cusip": "98986M103", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "https://www.zynex.com/", "description": "Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.", "ceo": "Mr. Thomas Sandgaard", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "283", "phone": "13038673904", "address": "9555 MAROON CIRCLE", "city": "Englewood", "state": "COLORADO", "zip": "80112", "dcfDiff": null, "dcf": 14.1834, "image": "https://financialmodelingprep.com/image-stock/ZYXI.jpg", "ipoDate": "2002-11-27", "defaultImage": true}}}, "news": ["https://investorplace.com/2021/01/map-a-course-for-breakthrough-science-with-bngo-stock/", "https://investorplace.com/2021/01/stock-market-movers-shakers-5-big-names-business-cciv-stock-tsla-arkx/", "https://deadline.com/2021/01/cinedigm-acquires-fandor-film-streaming-service-free-tier-1234676152/", "https://investorplace.com/2021/01/7-penny-stocks-that-could-see-a-surge-in-a-biden-presidency/", "https://www.forbes.com/sites/dbloom/2021/01/19/cinedigm-buys-fandor-plans-larger-streaming-video-rollup/"]}